Multicenter Phase 2 Trial of G-CSF Priming, Clofarabine, and High Dose Cytarabine (GCLAC) for Newly Diagnosed Acute Myeloid Leukemia, Advanced Myelodysplastic Syndrome or Advanced Myeloproliferative Neoplasm

被引：0
|
作者：
Becker, Pamela S. [1 ]
Medeiros, Bruno C. [2 ]
Stein, Anthony Selwyn [3 ]
Appelbaum, Frederick R. [4 ]
Scott, Bart L. [5 ]
Delaney, Colleen [5 ,6 ]
Othus, Megan
Hendrie, Paul C.
Gardner, Kelda M. [5 ]
Petersdorf, Stephen [7 ]
Pagel, John M.
Walter, Roland B. [5 ]
Parks, Cynthia [1 ]
Estey, Elihu H. [5 ]
机构：
[1] Univ Washington, Div Hematol, Seattle, WA 98195 USA
[2] Stanford Comprehens Canc Ctr, Div Hematol, Stanford, CA USA
[3] City Hope Natl Med Ctr, Hematol & HCT, Duarte, CA USA
[4] Univ Washington, Dept Med, Div Med Oncol, Seattle, WA USA
[5] Fred Hutchinson Canc Res Ctr, Div Clin Res, Seattle, WA 98104 USA
[6] UW, Dept Pediat, Seattle, WA USA
[7] Univ Washington, Fred Hutchinson Canc Res Ctr, Seattle, WA 98195 USA
来源：
BLOOD | 2012年 / 120卷 / 21期
关键词：
D O I：
10.1182/blood.V120.21.3594.3594
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
3594
引用
收藏
页数：2
相关论文
共 50 条
  • [41] PHASE 1 TRIAL OF G-CSF, CLADRIBINE, CYTARABINE, AND DOSE-ESCALATED MITOXANTRONE (G-CLAM) IN ADULTS WITH NEWLY DIAGNOSED AML OR HIGH-RISK MDS
    Anwar, A.
    Halpern, A.
    Scott, B.
    Becker, P.
    Othus, M.
    Hendrie, P.
    Ranker, E.
    Perdue, A.
    Chen, T.
    Buckley, S.
    Orlowski, K.
    Powell, M.
    Appelbaum, F.
    Estey, E.
    Walter, R.
    HAEMATOLOGICA, 2015, 100 : 219 - 219
  • [42] A Phase 1-2 Study of a Farnesyltransferase Inhibitor, Tipifarnib, Combined With Idarubicin and Cytarabine for Patients With Newly Diagnosed Acute Myeloid Leukemia and High-Risk Myelodysplastic Syndrome
    Jabbour, Elias
    Kantarjian, Hagop
    Ravandi, Farhad
    Garcia-Manero, Guillermo
    Estrov, Zeev
    Verstovsek, Srdan
    O'Brien, Susan
    Faderl, Stefan
    Thomas, Deborah A.
    Wright, John J.
    Cortes, Jorge
    CANCER, 2011, 117 (06) : 1236 - 1244
  • [43] Interferon alfa-2B plus low-dose cytarabine for the maintenance of remission in acute myeloid leukemia and advanced myelodysplastic syndrome.
    Koller, CA
    BLOOD, 2001, 98 (11) : 214B - 214B
  • [44] AGGRESSIVE CHEMOTHERAPY COMBINED WITH G-CSF AND MAINTENANCE THERAPY WITH INTERLEUKIN-2 FOR PATIENTS WITH ADVANCED MYELODYSPLASTIC SYNDROME, SUBACUTE OR SECONDARY ACUTE MYELOID-LEUKEMIA - INITIAL RESULTS
    GANSER, A
    HEIL, G
    KOLBE, K
    MASCHMEYER, G
    FISCHER, JT
    BERGMANN, L
    MITROU, PS
    HEIT, W
    HEIMPEL, H
    HUBER, C
    HOELZER, D
    ANNALS OF HEMATOLOGY, 1993, 66 (03) : 123 - 125
  • [45] Etoposide in combination with low-dose CAG (cytarabine, aclarubicin, G-CSF) for the treatment of relapsed or refractory acute myeloid leukemia: A multicenter, randomized control trial in southwest China
    Zhang, Xi
    Li, Yunlong
    Zhang, Yanqi
    Chen, Xinghua
    Zhang, Cheng
    Gao, Li
    Kong, Peiyan
    Liu, Yao
    Wen, Qin
    Zeng, Yunjing
    Wang, Qingyu
    Su, Yi
    Wang, Chunsen
    Wang, Sanbin
    Yuan, Zhong
    Gao, Lei
    LEUKEMIA RESEARCH, 2013, 37 (06) : 657 - 664
  • [46] FLAG-IDA regimen (fludarabine, cytarabine, idarubicin and G-CSF) in the treatment of patients with high-risk acute myeloid leukemia and myelodysplastic syndromes
    Montesinos, Pau
    de la Rubia, Javier
    Orti, Guillermo
    Sanz, Jaime
    Martinez, David
    Mendoza, Ninotchka
    Scaff, Miguel
    Paciello, Mariliz
    Romero, Monica
    Martin, Guillermo
    Lorenzo, Ignacio
    Martinez, Jesus
    Algarra, Lorenzo
    Jarque, Isidro
    Perez-Sirvent, Mariluz
    Sanz, Guillermo
    Sanz, Miguel A.
    BLOOD, 2007, 110 (11) : 843A - 843A
  • [47] A Randomized Phase II Study of Tosedostat in Combination with Either Cytarabine or Decitabine in Newly Diagnosed Older Patients with Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome
    Mawad, Raya
    Becker, Pamela S.
    Hendrie, Paul C.
    Scott, Bart L.
    Wood, Brent L.
    Dean, Carol
    Sandhu, Vicky
    Deeg, H. Joachim
    Walter, Roland B.
    Wang, Lixia
    Singer, Jack
    Estey, Elihu H.
    Pagel, John
    BLOOD, 2014, 124 (21)
  • [48] Randomized trial of GM-CSF and G-CSF following high-dose cytarabine and mitoxantrone chemotherapy for relapsed and refractory acute leukemia.
    Baer, Maria R.
    Ford, Laurie A.
    Bundy, Brian N.
    Tighe, Sheila M.
    O'Loughlin, Kieran L.
    Slack, James L.
    Wetzler, Meir
    Wallace, Paul K.
    BLOOD, 2006, 108 (11) : 223B - 223B
  • [49] Final Report of a Phase II Trial of Vorinostat with Idarubicin and Cytarabine for Patients with Newly Diagnosed Acute Myelogenous Leukemia (AML) or Myelodysplastic Syndrome (MDS)
    Garcia-Manero, Guillermo
    Tambaro, Francesco Paolo
    Bekele, Nebiyou
    Yang, Rui
    Ravandi, Farhad
    Jabbour, Elias
    Borthakur, Gautam
    Kadia, Tapan
    Konopleva, Marina
    Faderl, Stefan
    Cortes, Jorge E.
    Brandt, Mark
    Hu, Yumin
    McCue, Deborah
    Newsome, Willie Mae
    Pierce, Sherry
    DeLima, Marcos
    Kantarjian, Hagop M.
    BLOOD, 2011, 118 (21) : 346 - 347
  • [50] Clofarabine plus cytarabine (ara-C) is an active induction regimen for newly diagnosed patients (pts) ≤ age 50 with acute myeloid leukemia (AML) and high-risk myelodysplastic syndrome (MOS).
    Faderl, S
    Gandhi, V
    Giles, F
    Estey, E
    Garcia-Manero, G
    O'Brien, S
    Wierda, W
    Kwari, M
    Craig, A
    Kantarjian, HM
    JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (14) : 584S - 584S
12345